Q1 EPS Estimates for Globus Medical Lowered by Roth Capital

Globus Medical, Inc. (NYSE:GMED) – Roth Capital decreased their Q1 2025 earnings per share estimates for Globus Medical in a report released on Friday, February 21st. Roth Capital analyst J. Wittes now expects that the medical device company will post earnings of $0.74 per share for the quarter, down from their prior estimate of $0.75. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical’s Q2 2025 earnings at $0.82 EPS, Q3 2025 earnings at $0.85 EPS, FY2025 earnings at $3.40 EPS, FY2026 earnings at $4.29 EPS and FY2027 earnings at $4.75 EPS.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.10. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%. The firm had revenue of $657.29 million during the quarter, compared to analysts’ expectations of $646.19 million.

Several other research analysts have also recently weighed in on GMED. StockNews.com upgraded Globus Medical from a “hold” rating to a “buy” rating in a research note on Friday, February 14th. Morgan Stanley upgraded Globus Medical from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $83.00 to $100.00 in a research note on Monday, December 2nd. Canaccord Genuity Group lifted their price objective on Globus Medical from $92.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, January 10th. Wells Fargo & Company cut their price objective on Globus Medical from $95.00 to $93.00 and set an “overweight” rating for the company in a report on Friday. Finally, Royal Bank of Canada lifted their price objective on Globus Medical from $80.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, November 6th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $96.91.

Globus Medical Price Performance

GMED stock opened at $80.43 on Monday. Globus Medical has a 1-year low of $49.33 and a 1-year high of $94.93. The business has a fifty day moving average price of $86.72 and a 200-day moving average price of $79.16. The stock has a market capitalization of $10.95 billion, a P/E ratio of 107.24, a P/E/G ratio of 1.61 and a beta of 1.19.

Insider Buying and Selling at Globus Medical

In other news, CFO Keith W. Pfeil sold 14,167 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $88.29, for a total value of $1,250,804.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Kelly Huller sold 2,500 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $87.00, for a total value of $217,500.00. The disclosure for this sale can be found here. 18.54% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Globus Medical

A number of hedge funds have recently made changes to their positions in GMED. Creative Planning boosted its stake in shares of Globus Medical by 5.1% in the third quarter. Creative Planning now owns 6,471 shares of the medical device company’s stock worth $463,000 after acquiring an additional 314 shares during the period. Private Advisor Group LLC lifted its position in shares of Globus Medical by 16.4% in the third quarter. Private Advisor Group LLC now owns 4,236 shares of the medical device company’s stock worth $303,000 after buying an additional 598 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Globus Medical by 7,318.2% in the third quarter. International Assets Investment Management LLC now owns 56,230 shares of the medical device company’s stock worth $40,230,000 after buying an additional 55,472 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Globus Medical by 3.0% in the third quarter. Assenagon Asset Management S.A. now owns 54,023 shares of the medical device company’s stock worth $3,865,000 after buying an additional 1,558 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its position in shares of Globus Medical by 2.5% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 5,637 shares of the medical device company’s stock worth $403,000 after buying an additional 140 shares in the last quarter. Institutional investors own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.